The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Open accessAbstract
INTRODUCTION Final overall survival (OS) analyses are presented for EGFR mutations and liver or brain metastases subgroups in the phase III IMpower150 study (NCT02366143) evaluating atezolizumab+bevacizumab+carboplatin/paclitaxel (ABCP) or atezolizumab+carboplatin/paclitaxel (ACP) vs bevacizumab+carboplatin/paclitaxel (BCP). METHODS Overall, 1202 patients (intention-to-treat [ITT] population) with chemotherapy-naive, metastatic, nonsquamous non-small cell lung cancer were randomized to ABCP, ACP or BCP. Patients with treated, stable brain metastases were permitted. OS was assessed in EGFR mutations and baseline liver metastases subgroups; rate and time to development (TTD) of new brain metastases was assessed in ITT patients. RESULTS At data cutoff (September 13, 2019; median follow-up, 39.3 months), OS improvements were sustained with ABCP versus BCP in sensitizing EGFR mutations (all: hazard ratio [HR] 0.60; 95% CI: 0.31-1.14; prior tyrosine kinase inhibitor [TKI]: HR 0.74; 95% CI: 0.38-1.46) and baseline liver metastases (HR 0.68; 95% CI: 0.45-1.02) subgroups. ACP did not show survival benefit versus BCP in sensitizing EGFR mutations (all: HR 1.0; 95% CI: 0.57-1.74; prior TKI: HR 1.22; 95% CI: 0.68-2.22) or liver metastases (HR 1.01; 95% CI: 0.68-1.51) subgroups. Overall, 100 patients (8.3%) developed new brain metastases. While not formally evaluated, an improvement toward delayed TTD was seen with ABCP vs BCP (HR, 0.68; 95% CI: 0.39-1.19). CONCLUSIONS This final exploratory analysis showed OS benefits for ABCP versus BCP in patients with sensitizing EGFR mutations, including those with prior TKI failures, and with liver metastases, although these results should be interpreted with caution. The impact of ABCP on delaying the development of new brain lesions requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“1 receptors.(2,3) Atezolizumab, as monotherapy and in combination with chemotherapy, was found to have efficacy in patients with NSCLC.”
BackgroundPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · cited 8×
“1 receptors.2,3 Atezolizumab, as monotherapy and in combination with chemotherapy, was found to have efficacy in patients with NSCLC.4–8 The recombinant humanized vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab was found to substantially improve overall survival (OS) when combined with chemot…”
BackgroundSelf-citationButte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Self-citationMetastatic sites and survival in lung cancer
Riihimäki, M., Hemminki, A., Fallah, M., Thomsen, H., Sundquist, K., Sundquist, J., & Hemminki, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.020 · Cited by 888
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Self-citationThe PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Dammeijer, F., van Gulijk, M., Mulder, E. E., Lukkes, M., Klaase, L., van den Bosch, T., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 695
Self-citationSperduto, P. W., Yang, T. J., Beal, K., Pan, H., Brown, P. D., Bangdiwala, A., Shanley, R., Yeh, N., Gaspar, L. E., Braunstein, S., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3834 · Cited by 659
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0325 · Cited by 560
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Specific organ metastases and survival in metastatic non-small-cell lung cancer
TAMURA, T., KURISHIMA, K., NAKAZAWA, K., KAGOHASHI, K., ISHIKAWA, H., SATOH, H., & HIZAWA, N. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.410 · Cited by 341
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., Sayegh, M. H., Blazar, B. R., Freeman, G. J., & Sharpe, A. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003496 · Cited by 202
Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
Vennapusa, B., Baker, B., Kowanetz, M., Boone, J., Menzl, I., Bruey, J.-M., Fine, G., Mariathasan, S., McCaffery, I., Mocci, S., et al. (2019) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000594 · Cited by 181
Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 167
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
Ren, Y., Dai, C., Zheng, H., Zhou, F., She, Y., Jiang, G., Fei, K., Yang, P., Xie, D., & Chen, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10644 · Cited by 163
Yang, J., Riella, L. V., Chock, S., Liu, T., Zhao, X., Yuan, X., Paterson, A. M., Watanabe, T., Vanguri, V. K., Yagita∥, H., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100056 · Cited by 146
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0582 · Cited by 119
Self-citationPao, W. J., Ooi, C.-H., Birzele, F., Ruefli-Brasse, A. A., Cannarile, M. A., Reis, B., Scharf, S. H., Schubert, D. A., Hatje, K., Pelletier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1320 · Cited by 99
Zhuang, X., Zhao, C., Li, J., Su, C., Chen, X., Ren, S., Li, X., & Zhou, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2183 · Cited by 95
Hung, M., Chen, I., Lin, P.-Y., Lung, J.-H., Li, Y., Lin, Y., Yang, C., & Tsai, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.5287 · Cited by 88
Horn, L., Gettinger, S. N., Gordon, M. S., Herbst, R. S., Gandhi, L., Felip, E., Sequist, L. V. D., Spigel, D. R., Antonia, S. J., Balmanoukian, A. S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.031 · Cited by 55
Mu, Y., Hao, X., Yang, K., Ma, D., Wang, S., Xu, Z., Li, J., & Xing, P. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00644-6 · Cited by 42
Jin, R., Zhao, J., Xia, L., Li, Q., Li, W., Peng, L., & Xia, Y. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920930333 · Cited by 42
Immune Checkpoint Blockade – How Does It Work in Brain Metastases?
Lorger, M., Andreou, T., Fife, C. M., & James, F. R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00282 · Cited by 35
Li, S., Sun, S., Xiang, H., Yang, J. L., Peng, M., & Gao, Q. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1746113 · Cited by 32
Fu, Y., Hu, J., Du, N., Jiao, S., Fang, L., Li, X., Ma, J., Zhao, H., & Kang, H. (2015) · Journal of Chemotherapy · doi:10.1179/1973947815y.0000000045 · Cited by 30
Chang, Y.-P., Chen, Y., Lai, C., Lin, C.-Y., Fang, W., Huang, C.-H., Li, S.-H., Chen, H., Wang, C., & Lin, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178676 · Cited by 30
Pillai, R. N., Kamphorst, A. O., Owonikoko, T. K., Behera, M., Pakkala, S., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e20665 · Cited by 12
Cited by
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Self-citationNon‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Metadata
- Authors
- Nogami, N., Barlesi, F., Socinski, M. A., Reck, M., Thomas, C. A., Cappuzzo, F., Mok, T. S. K., Finley, G., Aerts, J. G., Orlandi, F., Moro-Sibilot, D., Jotte, R. M., Stroyakovskiy, D., Villaruz, L. C., Rodríguez-Abreu, D., Wan-Teck Lim, D., Merritt, D., Coleman, S., Lee, A., Shankar, G., Yu, W., Bara, I., & Nishio, M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 17
- Issue
- 2
- Pages
- 309-323
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3204380660
- Cited by
- 302
- References
- 43
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.